Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AKR7A2P pseudogene 1 (AKR7A2P2) is a processed pseudogene derived from the functional AKR7A2 gene, which encodes an aldo-keto reductase enzyme. As a pseudogene, AKR7A2P2 lacks the ability to encode a functional protein product due to disabling mutations and/or loss of regulatory elements[2]. Pseudogenes may arise through mutation, duplication, or retrotransposition mechanisms, and AKR7A2P2 likely belongs to the processed category, which forms via reverse transcription and genomic integration of AKR7A2 mRNA. While some pseudogenes can regulate parental gene expression through RNA-mediated mechanisms (such as acting as competing endogenous RNAs or miRNA sponges), no specific regulatory function or disease association is documented for AKR7A2P2[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on AKR7A2P pseudogene 1 (AKR7A2P2).